{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:33:52Z","timestamp":1784306032166,"version":"3.55.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002283","name":"Alzheimer\u2019s Research UK","doi-asserted-by":"publisher","award":["ARUK-RADF2019A-003"],"award-info":[{"award-number":["ARUK-RADF2019A-003"]}],"id":[{"id":"10.13039\/501100002283","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["U01AG046139"],"award-info":[{"award-number":["U01AG046139"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["U01TR003715"],"award-info":[{"award-number":["U01TR003715"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The accumulation of \u03b1-synuclein (\u03b1-syn) in intracellular formations known as Lewy bodies (LBs) is associated with several neurodegenerative diseases including Parkinson\u2019s disease and Lewy Body Dementia. There is still limited understanding of how \u03b1-syn and LB formation is associated with cellular dysfunction and degeneration in these diseases. To examine the clearance and production dynamics of \u03b1-syn we transduced organotypic murine brain slice cultures (BSCs) with recombinant adeno-associated viruses (rAAVs) to express Dendra2-tagged human wild-type (WT) and mutant A53T \u03b1-syn, with and without the addition of exogenous \u03b1-syn fibrillar seeds and tracked them over several weeks in culture using optical pulse labeling. We found that neurons expressing WT or mutant A53T human \u03b1-syn show similar rates of \u03b1-syn turnover even when insoluble, phosphorylated Ser129 \u03b1-syn has accumulated. Taken together, this data reveals \u03b1-syn aggregation and overexpression, pSer129 \u03b1-syn, nor the A53T mutation affect \u03b1-syn dynamics in this system. Prion-type seeding with exogenous \u03b1-syn fibrils significantly slows \u03b1-syn turnover, in the absence of toxicity but is associated with the accumulation of anti-p62 immunoreactivity and Thiazin Red positivity. Prion-type induction of \u03b1-syn aggregation points towards a potential protein clearance deficit in the presence of fibrillar seeds and the ease of this system to explore precise mechanisms underlying these processes. This system facilitates the exploration of \u03b1-syn protein dynamics over long-term culture periods. This platform can further be exploited to provide mechanistic insight on what drives this slowing of \u03b1-syn turnover and how therapeutics, other genes or different \u03b1-syn mutations may affect \u03b1-syn protein dynamics.<\/jats:p>","DOI":"10.1038\/s41531-022-00434-4","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T02:07:04Z","timestamp":1671415624000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Optical pulse labeling studies reveal exogenous seeding slows \u03b1-synuclein clearance"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7969-5084","authenticated-orcid":false,"given":"Cara L.","family":"Croft","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giavanna","family":"Paterno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ava R.","family":"Vause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyla A.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshall S.","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey A.","family":"Moran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro E.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit I.","family":"Giasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1867-7071","authenticated-orcid":false,"given":"Todd E.","family":"Golde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,19]]},"reference":[{"key":"434_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13195-014-0073-2","volume":"6","author":"WS Kim","year":"2014","unstructured":"Kim, W. S., K\u00e5gedal, K. & Halliday, G. M. Alpha-synuclein biology in Lewy body diseases. Alzheimers Res Ther. 6, 73\u201373 (2014).","journal-title":"Alzheimers Res Ther."},{"key":"434_CR2","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S1474-4422(15)00006-X","volume":"14","author":"B Dehay","year":"2015","unstructured":"Dehay, B. et al. Targeting \u03b1-synuclein for treating Parkinson\u2019s disease: mechanistic and therapeutic considerations. Lancet Neurol. 14, 855\u2013866 (2015).","journal-title":"Lancet Neurol."},{"key":"434_CR3","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","volume":"95","author":"MG Spillantini","year":"1998","unstructured":"Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M. & Goedert, M. \u03b1-Synuclein in filamentous inclusions of Lewy bodies from Parkinson\u2019s disease and dementia with Lewy bodies. Proc. Natl Acad. Sci. 95, 6469\u20136473 (1998).","journal-title":"Proc. Natl Acad. Sci."},{"key":"434_CR4","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini, M. G. et al. \u03b1-Synuclein in Lewy bodies. Nature 388, 839\u2013840 (1997).","journal-title":"Nature"},{"key":"434_CR5","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/ncb748","volume":"4","author":"H Fujiwara","year":"2002","unstructured":"Fujiwara, H. et al. \u03b1-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4, 160 (2002).","journal-title":"Nat. Cell Biol."},{"key":"434_CR6","doi-asserted-by":"publisher","first-page":"29739","DOI":"10.1074\/jbc.M600933200","volume":"281","author":"JP Anderson","year":"2006","unstructured":"Anderson, J. P. et al. Phosphorylation of Ser-129 Is the Dominant Pathological Modification of \u03b1-Synuclein in Familial and Sporadic Lewy Body Disease. J. Biol. Chem. 281, 29739\u201329752 (2006).","journal-title":"J. Biol. Chem."},{"key":"434_CR7","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S1474-4422(19)30287-X","volume":"19","author":"C Blauwendraat","year":"2020","unstructured":"Blauwendraat, C., Nalls, M. A. & Singleton, A. B. The genetic architecture of Parkinson\u2019s disease. Lancet Neurol. 19, 170\u2013178 (2020).","journal-title":"Lancet Neurol."},{"key":"434_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41583-020-00416-6","volume":"22","author":"MB Fares","year":"2021","unstructured":"Fares, M. B., Jagannath, S. & Lashuel, H. A. Reverse engineering Lewy bodies: how far have we come and how far can we go? Nat. Rev. Neurosci. 22, 111\u2013131 (2021).","journal-title":"Nat. Rev. Neurosci."},{"key":"434_CR9","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.3233\/JPD-179005","volume":"7","author":"M Goedert","year":"2017","unstructured":"Goedert, M., Jakes, R. & Spillantini, M. G. The Synucleinopathies: Twenty Years On. J. Parkinsons Dis. 7, S51\u2013S69 (2017).","journal-title":"J. Parkinsons Dis."},{"key":"434_CR10","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/s41593-019-0423-2","volume":"22","author":"SH Shahmoradian","year":"2019","unstructured":"Shahmoradian, S. H. et al. Lewy pathology in Parkinson\u2019s disease consists of crowded organelles and lipid membranes. Nat. Neurosci. 22, 1099\u20131109 (2019).","journal-title":"Nat. Neurosci."},{"key":"434_CR11","doi-asserted-by":"crossref","unstructured":"Moors, T. E. et al. The subcellular arrangement of alpha-synuclein proteoforms in the Parkinson\u2019s disease brain as revealed by multicolor STED microscopy. Acta Neuropathol. 142, 423\u2013448 (2021).","DOI":"10.1007\/s00401-021-02329-9"},{"key":"434_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41531-021-00203-9","volume":"7","author":"LMA Oliveira","year":"2021","unstructured":"Oliveira, L. M. A. et al. Alpha-synuclein research: defining strategic moves in the battle against Parkinson\u2019s disease. NPJ Parkinson\u2019s Dis. 7, 65\u201365 (2021).","journal-title":"NPJ Parkinson\u2019s Dis."},{"key":"434_CR13","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1474-4422(21)00061-2","volume":"20","author":"N Vijiaratnam","year":"2021","unstructured":"Vijiaratnam, N., Simuni, T., Bandmann, O., Morris, H. R. & Foltynie, T. Progress towards therapies for disease modification in Parkinson\u2019s disease. Lancet Neurol. 20, 559\u2013572 (2021).","journal-title":"Lancet Neurol."},{"key":"434_CR14","doi-asserted-by":"publisher","first-page":"134316","DOI":"10.1016\/j.neulet.2019.134316","volume":"709","author":"MX Henderson","year":"2019","unstructured":"Henderson, M. X., Trojanowski, J. Q. & Lee, V. M. Y. \u03b1-Synuclein pathology in Parkinson\u2019s disease and related \u03b1-synucleinopathies. Neurosci. Lett. 709, 134316 (2019).","journal-title":"Neurosci. Lett."},{"key":"434_CR15","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1084\/jem.20182184","volume":"216","author":"CL Croft","year":"2019","unstructured":"Croft, C. L. et al. rAAV-based brain slice culture models of Alzheimer\u2019s and Parkinson\u2019s disease inclusion pathologies. J. Exp. Med 216, 539\u2013555 (2019).","journal-title":"J. Exp. Med"},{"key":"434_CR16","doi-asserted-by":"publisher","first-page":"e0252635","DOI":"10.1371\/journal.pone.0252635","volume":"16","author":"S Elfarrash","year":"2021","unstructured":"Elfarrash, S. et al. Polo-like kinase 2 inhibition reduces serine-129 phosphorylation of physiological nuclear alpha-synuclein but not of the aggregated alpha-synuclein. PLOS One. 16, e0252635 (2021).","journal-title":"PLOS One."},{"key":"434_CR17","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00401-021-02264-9","volume":"141","author":"CL Croft","year":"2021","unstructured":"Croft, C. L. et al. Photodynamic studies reveal rapid formation and appreciable turnover of tau inclusions. Acta Neuropathologica. 141, 359\u2013381 (2021).","journal-title":"Acta Neuropathologica."},{"key":"434_CR18","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1038\/nprot.2007.291","volume":"2","author":"DM Chudakov","year":"2007","unstructured":"Chudakov, D. M., Lukyanov, S. & Lukyanov, K. A. Tracking intracellular protein movements using photoswitchable fluorescent proteins PS-CFP2 and Dendra2. Nat. Protoc. 2, 2024 (2007).","journal-title":"Nat. Protoc."},{"key":"434_CR19","doi-asserted-by":"crossref","unstructured":"Chudakov, D. M., Lukyanov, S. & Lukyanov, K. A. Using photoactivatable fluorescent protein Dendra2 to track protein movement. Biotechniques 42, 553\u2013563 (2018).","DOI":"10.2144\/000112470"},{"key":"434_CR20","doi-asserted-by":"publisher","first-page":"E8274","DOI":"10.1073\/pnas.1703420114","volume":"114","author":"I Inigo-Marco","year":"2017","unstructured":"Inigo-Marco, I. et al. E46K alpha-synuclein pathological mutation causes cell-autonomous toxicity without altering protein turnover or aggregation. Proc. Natl Acad. Sci. 114, E8274\u2013E8283 (2017).","journal-title":"Proc. Natl Acad. Sci."},{"key":"434_CR21","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1126\/science.1101738","volume":"305","author":"AM Cuervo","year":"2004","unstructured":"Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T. & Sulzer, D. Impaired Degradation of Mutant \u03b1-Synuclein by Chaperone-Mediated Autophagy. Science 305, 1292\u20131295 (2004).","journal-title":"Science"},{"key":"434_CR22","doi-asserted-by":"publisher","first-page":"33855","DOI":"10.1074\/jbc.274.48.33855","volume":"274","author":"MC Bennett","year":"1999","unstructured":"Bennett, M. C. et al. Degradation of \u03b1-Synuclein by Proteasome. J. Biol. Chem. 274, 33855\u201333858 (1999).","journal-title":"J. Biol. Chem."},{"key":"434_CR23","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.csbj.2021.12.017","volume":"20","author":"JC Shillcock","year":"2022","unstructured":"Shillcock, J. C., Hastings, J., Riguet, N. & Lashuel, H. A. Non-monotonic fibril surface occlusion by GFP tags from coarse-grained molecular simulations. Comput Struct. Biotechnol. J. 20, 309\u2013321 (2022).","journal-title":"Comput Struct. Biotechnol. J."},{"key":"434_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26684-z","volume":"12","author":"N Riguet","year":"2021","unstructured":"Riguet, N. et al. Nuclear and cytoplasmic huntingtin inclusions exhibit distinct biochemical composition, interactome and ultrastructural properties. Nat. Commun. 12, 6579 (2021).","journal-title":"Nat. Commun."},{"key":"434_CR25","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.tins.2016.09.003","volume":"39","author":"NP Visanji","year":"2016","unstructured":"Visanji, N. P. et al. \u03b1-Synuclein-Based Animal Models of Parkinson\u2019s Disease: Challenges and Opportunities in a New Era. Trends Neurosci. 39, 750\u2013762 (2016).","journal-title":"Trends Neurosci."},{"key":"434_CR26","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s40478-019-0865-5","volume":"7","author":"S Elfarrash","year":"2019","unstructured":"Elfarrash, S. et al. Organotypic slice culture model demonstrates inter-neuronal spreading of alpha-synuclein aggregates. Acta Neuropathol. Commun. 7, 213 (2019).","journal-title":"Acta Neuropathol. Commun."},{"key":"434_CR27","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13024-021-00471-2","volume":"16","author":"M Barth","year":"2021","unstructured":"Barth, M. et al. Microglial inclusions and neurofilament light chain release follow neuronal \u03b1-synuclein lesions in long-term brain slice cultures. Mol. Neurodegen. 16, 54\u201354 (2021).","journal-title":"Mol. Neurodegen."},{"key":"434_CR28","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.3233\/JPD-202026","volume":"10","author":"A Roux","year":"2020","unstructured":"Roux, A., Wang, X., Becker, K. & Ma, J. Modeling \u03b1-Synucleinopathy in Organotypic Brain Slice Culture with Preformed \u03b1-Synuclein Amyloid Fibrils. J. Parkinsons Dis. 10, 1397\u20131410 (2020).","journal-title":"J. Parkinsons Dis."},{"key":"434_CR29","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s00401-020-02227-6","volume":"140","author":"Q Wu","year":"2020","unstructured":"Wu, Q. et al. Neuronal activity modulates alpha-synuclein aggregation and spreading in organotypic brain slice cultures and in vivo. Acta Neuropathol. 140, 831\u2013849 (2020).","journal-title":"Acta Neuropathol."},{"key":"434_CR30","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/jnen\/62.12.1241","volume":"62","author":"E Kuusisto","year":"2003","unstructured":"Kuusisto, E., Parkkinen, L. & Alafuzoff, I. Morphogenesis of Lewy Bodies: Dissimilar Incorporation of \u03b1-Synuclein, Ubiquitin, and p62. J. Neuropathol. Exp. Neurol. 62, 1241\u20131253 (2003).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"434_CR31","doi-asserted-by":"publisher","first-page":"4971","DOI":"10.1073\/pnas.1913904117","volume":"117","author":"A-L Mahul-Mellier","year":"2020","unstructured":"Mahul-Mellier, A.-L. et al. The process of Lewy body formation, rather than simply \u03b1-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proc. Natl Acad. Sci. 117, 4971\u20134982 (2020).","journal-title":"Proc. Natl Acad. Sci."},{"key":"434_CR32","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1006\/exnr.2002.7961","volume":"177","author":"M Sakamoto","year":"2002","unstructured":"Sakamoto, M. et al. Heterogeneity of Nigral and Cortical Lewy Bodies Differentiated by Amplified Triple-Labeling for Alpha-Synuclein, Ubiquitin, and Thiazin Red. Exp. Neurol. 177, 88\u201394 (2002).","journal-title":"Exp. Neurol."},{"key":"434_CR33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.neuron.2011.08.033","volume":"72","author":"LA Volpicelli-Daley","year":"2011","unstructured":"Volpicelli-Daley, L. A. et al. Exogenous \u03b1-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72, 57\u201371 (2011).","journal-title":"Neuron"},{"key":"434_CR34","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/jnc.14704","volume":"150","author":"L Stefanis","year":"2019","unstructured":"Stefanis, L. et al. How is alpha-synuclein cleared from the cell? J. Neurochemistry. 150, 577\u2013590 (2019).","journal-title":"J. Neurochemistry."},{"key":"434_CR35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40478-017-0452-6","volume":"5","author":"S Arawaka","year":"2017","unstructured":"Arawaka, S., Sato, H., Sasaki, A., Koyama, S. & Kato, T. Mechanisms underlying extensive Ser129-phosphorylation in \u03b1-synuclein aggregates. Acta Neuropathol. Commun. 5, 48\u201348 (2017).","journal-title":"Acta Neuropathol. Commun."},{"key":"434_CR36","doi-asserted-by":"publisher","first-page":"E3945","DOI":"10.1073\/pnas.1309991110","volume":"110","author":"A Oueslati","year":"2013","unstructured":"Oueslati, A., Schneider, B. L., Aebischer, P. & Lashuel, H. A. Polo-like kinase 2 regulates selective autophagic alpha-synuclein clearance and suppresses its toxicity in vivo. Proc. Natl Acad. Sci.110, E3945\u2013E3954 (2013).","journal-title":"Proc. Natl Acad. Sci."},{"key":"434_CR37","doi-asserted-by":"publisher","first-page":"7400","DOI":"10.1523\/JNEUROSCI.1370-04.2004","volume":"24","author":"W Li","year":"2004","unstructured":"Li, W. et al. Stabilization of alpha-synuclein protein with aging and familial parkinson\u2019s disease-linked A53T mutation. J. Neurosci. 24, 7400\u20137409 (2004).","journal-title":"J. Neurosci."},{"key":"434_CR38","doi-asserted-by":"publisher","first-page":"9549","DOI":"10.1523\/JNEUROSCI.21-24-09549.2001","volume":"21","author":"L Stefanis","year":"2001","unstructured":"Stefanis, L., Larsen, K. E., Rideout, H. J., Sulzer, D. & Greene, L. A. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J. Neurosci. 21, 9549\u20139560 (2001).","journal-title":"J. Neurosci."},{"key":"434_CR39","doi-asserted-by":"publisher","first-page":"8053","DOI":"10.1523\/JNEUROSCI.21-20-08053.2001","volume":"21","author":"E Paxinou","year":"2001","unstructured":"Paxinou, E. et al. Induction of {alpha}-Synuclein Aggregation by Intracellular Nitrative Insult. J. Neurosci. 21, 8053\u20138061 (2001).","journal-title":"J. Neurosci."},{"key":"434_CR40","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nchembio.1563","volume":"10","author":"SJ Barmada","year":"2014","unstructured":"Barmada, S. J. et al. Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models. Nat. Chem. Biol. 10, 677\u2013685 (2014).","journal-title":"Nat. Chem. Biol."},{"key":"434_CR41","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1074\/jbc.275.1.390","volume":"275","author":"M Okochi","year":"2000","unstructured":"Okochi, M. et al. Constitutive Phosphorylation of the Parkinson\u2019s Disease Associated \u03b1-Synuclein*. J. Biol. Chem. 275, 390\u2013397 (2000).","journal-title":"J. Biol. Chem."},{"key":"434_CR42","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s12035-012-8280-y","volume":"47","author":"K Wakabayashi","year":"2013","unstructured":"Wakabayashi, K. et al. The Lewy Body in Parkinson\u2019s Disease and Related Neurodegenerative Disorders. Mol. Neurobiol. 47, 495\u2013508 (2013).","journal-title":"Mol. Neurobiol."},{"key":"434_CR43","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.celrep.2015.01.060","volume":"10","author":"VR Osterberg","year":"2015","unstructured":"Osterberg, V. R. et al. Progressive Aggregation of Alpha-Synuclein and Selective Degeneration of Lewy Inclusion-Bearing Neurons in a Mouse Model of Parkinsonism. Cell Rep. 10, 1252\u20131260 (2015).","journal-title":"Cell Rep."},{"key":"434_CR44","doi-asserted-by":"publisher","first-page":"104876","DOI":"10.1016\/j.nbd.2020.104876","volume":"141","author":"HA Lashuel","year":"2020","unstructured":"Lashuel, H. A. Do Lewy bodies contain alpha-synuclein fibrils? and Does it matter? A brief history and critical analysis of recent reports. Neurobiol. Dis. 141, 104876 (2020).","journal-title":"Neurobiol. Dis."},{"key":"434_CR45","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13024-019-0346-0","volume":"14","author":"CL Croft","year":"2019","unstructured":"Croft, C. L., Futch, H. S., Moore, B. D. & Golde, T. E. Organotypic brain slice cultures to model neurodegenerative proteinopathies. Mol. Neurodegener. 14, 45\u201345 (2019).","journal-title":"Mol. Neurodegener."},{"key":"434_CR46","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00401-017-1746-2","volume":"134","author":"F Loria","year":"2017","unstructured":"Loria, F. et al. \u03b1-Synuclein transfer between neurons and astrocytes indicates that astrocytes play a role in degradation rather than in spreading. Acta Neuropathol. 134, 789\u2013808 (2017).","journal-title":"Acta Neuropathol."},{"key":"434_CR47","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1038\/s41467-020-15119-w","volume":"11","author":"I Choi","year":"2020","unstructured":"Choi, I. et al. Microglia clear neuron-released \u03b1-synuclein via selective autophagy and prevent neurodegeneration. Nat. Commun. 11, 1386 (2020).","journal-title":"Nat. Commun."},{"key":"434_CR48","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1128\/IAI.00642-12","volume":"81","author":"EA Harvie","year":"2013","unstructured":"Harvie, E. A., Green, J. M., Neely, M. N. & Huttenlocher, A. Innate immune response to Streptococcus iniae infection in zebrafish larvae. Infect. Immun. 81, 110\u2013121 (2013).","journal-title":"Infect. Immun."},{"key":"434_CR49","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13024-020-00361-z","volume":"15","author":"MS Goodwin","year":"2020","unstructured":"Goodwin, M. S. et al. Utilizing minimally purified secreted rAAV for rapid and cost-effective manipulation of gene expression in the CNS. Mol. Neurodegener. 15, 15 (2020).","journal-title":"Mol. Neurodegener."},{"key":"434_CR50","doi-asserted-by":"publisher","first-page":"592","DOI":"10.12688\/f1000research.14500.2","volume":"7","author":"CL Croft","year":"2018","unstructured":"Croft, C. L. & Noble, W. Preparation of organotypic brain slice cultures for the study of Alzheimer\u2019s disease. F1000Res 7, 592 (2018).","journal-title":"F1000Res"},{"key":"434_CR51","doi-asserted-by":"crossref","unstructured":"Sacino, A. N. et al. Conformational templating of \u03b1-synuclein aggregates in neuronal-glial cultures. Mol. Neurodegen. 8, 17 (2013).","DOI":"10.1186\/1750-1326-8-17"},{"key":"434_CR52","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/(SICI)1097-4547(20000215)59:4<528::AID-JNR8>3.0.CO;2-0","volume":"59","author":"BI Giasson","year":"2000","unstructured":"Giasson, B. I. et al. A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson\u2019s disease. J. Neurosci. Res. 59, 528\u2013533 (2000).","journal-title":"J. Neurosci. Res."},{"key":"434_CR53","doi-asserted-by":"publisher","first-page":"e0184731","DOI":"10.1371\/journal.pone.0184731","volume":"12","author":"J-KS Dhillon","year":"2017","unstructured":"Dhillon, J.-K. S. et al. A novel panel of \u03b1-synuclein antibodies reveal distinctive staining profiles in synucleinopathies. PLOS One. 12, e0184731 (2017).","journal-title":"PLOS One."},{"key":"434_CR54","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/NEN.0b013e3186fc995","volume":"67","author":"EA Waxman","year":"2008","unstructured":"Waxman, E. A. & Giasson, B. I. Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein. J. Neuropathol. Exp. Neurol. 67, 402\u2013416 (2008).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"434_CR55","doi-asserted-by":"publisher","first-page":"e0195211","DOI":"10.1371\/journal.pone.0195211","volume":"13","author":"CL Croft","year":"2018","unstructured":"Croft, C. L. et al. Novel monoclonal antibodies targeting the microtubule-binding domain of human tau. PloS One. 13, e0195211 (2018).","journal-title":"PloS One."},{"key":"434_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.97","volume":"8","author":"CL Croft","year":"2017","unstructured":"Croft, C. L. et al. Membrane association and release of wild-type and pathological tau from organotypic brain slice cultures. Cell Death Dis. 8, e2671 (2017).","journal-title":"Cell Death Dis."},{"key":"434_CR57","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1074\/jbc.M008919200","volume":"276","author":"BI Giasson","year":"2001","unstructured":"Giasson, B. I., Murray, I. V., Trojanowski, J. Q. & Lee, V. M. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J. Biol. Chem. 276, 2380\u20132386 (2001).","journal-title":"J. Biol. Chem."},{"key":"434_CR58","doi-asserted-by":"crossref","unstructured":"Ayers, J. I. et al. Robust Central Nervous System Pathology in Transgenic Mice following Peripheral Injection of \u03b1-Synuclein Fibrils. J. Virol. 91, e02095-16 (2017).","DOI":"10.1128\/JVI.02095-16"}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00434-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00434-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00434-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T03:04:55Z","timestamp":1671419095000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00434-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,19]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["434"],"URL":"https:\/\/doi.org\/10.1038\/s41531-022-00434-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1307173\/v1","asserted-by":"object"}]},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,19]]},"assertion":[{"value":"28 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.E.G. is a cofounder of Lacerta Therapeutic and Andante Biologics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"173"}}